London's AstraZeneca PLC said yesterday that it will pay $15.6 billion in cash to acquire FluMist developer MedImmune Inc. in a deal that highlights how far the pharmaceutical industry is willing to go to shore up its future by tapping into biotechnology.
...
The MedImmune acquisition will add 45 investigational drugs to the 113 AstraZeneca already has in its pipeline, along with three marketed products. Fifteen of the MedImmune's developing drugs are already in clinical testing.
more here.
